$1.52 Billion is the total value of Alphabet Inc.'s 28 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 20.8% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
JD | JD com Incspon adr cl a | $548,916,000 | +15.0% | 13,553,474 | 0.0% | 36.01% | +24.7% | |
LYFT | Lyft Inc | $344,458,000 | -37.6% | 12,828,964 | 0.0% | 22.60% | -32.3% | |
DXCM | Dexcom Inc | $216,946,000 | +23.1% | 805,681 | 0.0% | 14.23% | +33.6% | |
ONEM | New | 1Life Healthcare Inc | $112,224,000 | – | 6,183,154 | +100.0% | 7.36% | – |
RCUS | Arcus Biosciences Inc | $70,091,000 | +37.4% | 5,049,786 | 0.0% | 4.60% | +49.1% | |
VIR | Vir Biotechnology Inc | $57,117,000 | +172.5% | 1,666,666 | 0.0% | 3.75% | +195.7% | |
WORK | Slack Technologies Inc. | $34,886,000 | +19.4% | 1,299,771 | 0.0% | 2.29% | +29.5% | |
MGTA | Magenta Therapeutics Inc | $20,970,000 | -58.6% | 3,339,138 | 0.0% | 1.38% | -55.0% | |
SDGR | New | Schrodinger Inc | $19,349,000 | – | 448,722 | +100.0% | 1.27% | – |
RAPT | RAPT Therapeutics Inc | $17,783,000 | -23.0% | 836,059 | 0.0% | 1.17% | -16.4% | |
BEAM | New | Beam Therapeutics Inc | $11,946,000 | – | 663,691 | +100.0% | 0.78% | – |
CRWD | Crowdstrike Hldgs Inccl a | $9,522,000 | +11.6% | 171,020 | 0.0% | 0.62% | +21.1% | |
SPRO | Spero Therapeutics Inc | $8,989,000 | -16.0% | 1,112,473 | 0.0% | 0.59% | -8.8% | |
FULC | Buy | Fulcrum Therapeutics Inc | $8,670,000 | -27.1% | 726,189 | +1.7% | 0.57% | -20.9% |
CRTX | Cortexyme Inc | $8,626,000 | -18.8% | 189,122 | 0.0% | 0.57% | -11.8% | |
SNAP | Snap Inccl a | $6,227,000 | -27.2% | 523,710 | 0.0% | 0.41% | -20.9% | |
GRTS | Gritstone Oncology Inc | $5,407,000 | -35.1% | 929,022 | 0.0% | 0.36% | -29.6% | |
ALEC | Alector Inc | $4,244,000 | +40.1% | 175,866 | 0.0% | 0.28% | +51.9% | |
AUTL | Autolus Therapeutics PLCspon ads | $4,189,000 | -54.6% | 699,352 | 0.0% | 0.28% | -50.7% | |
EVLO | Evelo Biosciences Inc | $3,982,000 | -7.5% | 1,060,495 | 0.0% | 0.26% | +0.4% | |
CLDR | Cloudera Inc | $3,366,000 | -32.3% | 427,710 | 0.0% | 0.22% | -26.6% | |
IDYA | Ideaya Biosciences Inc | $3,103,000 | -45.1% | 753,187 | 0.0% | 0.20% | -40.4% | |
MWK | Mohawk Group Hldgs Inc | $1,785,000 | -71.3% | 1,055,954 | 0.0% | 0.12% | -68.9% | |
UBER | Sell | Uber Technologies Inc | $1,161,000 | -99.0% | 41,585 | -98.9% | 0.08% | -98.9% |
DBX | Dropbox Inccl a | $236,000 | +1.3% | 13,033 | 0.0% | 0.02% | +7.1% | |
NET | Exit | Cloudflare Inc | $0 | – | -1,632,519 | -100.0% | -1.68% | – |
FTSV | Exit | Forty Seven Inc | $0 | – | -1,030,644 | -100.0% | -2.45% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
SPERO THERAPEUTICS INC | 24 | Q3 2023 | 3.5% |
AUTOLUS THERAPEUTICS PLC | 22 | Q3 2023 | 2.8% |
Magenta Therapeutics Inc. | 21 | Q2 2023 | 3.8% |
DEXCOM INC | 20 | Q3 2023 | 17.4% |
Evelo Biosciences Inc. | 20 | Q1 2023 | 1.6% |
ALECTOR INC | 19 | Q3 2023 | 1.1% |
Lyft Inc | 18 | Q2 2023 | 51.9% |
QUINCE THERAPEUTICS INC | 18 | Q3 2023 | 0.6% |
Arcus Biosciences Inc | 17 | Q1 2022 | 12.7% |
FULCRUM THERAPEUTICS INC | 17 | Q3 2023 | 0.7% |
View Alphabet Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ARRIS International plc | February 14, 2019 | 7,603,500 | 4.4% |
View Alphabet Inc.'s complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
8-K | 2024-04-25 |
144 | 2024-04-17 |
144 | 2024-04-17 |
4 | 2024-04-17 |
4 | 2024-04-15 |
144 | 2024-04-12 |
4 | 2024-04-04 |
144 | 2024-04-03 |
144 | 2024-04-03 |
4 | 2024-04-02 |
View Alphabet Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.